{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T09:19:49Z","timestamp":1720084789565},"reference-count":24,"publisher":"Impact Journals, LLC","issue":"36","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,9,6]]},"DOI":"10.18632\/oncotarget.11281","type":"journal-article","created":{"date-parts":[[2016,8,13]],"date-time":"2016-08-13T14:49:48Z","timestamp":1471099788000},"page":"58234-58243","source":"Crossref","is-referenced-by-count":6,"title":["A clinical observation of Chinese chronic myelogenous leukemia patients after discontinuation of tyrosine kinase inhibitors"],"prefix":"10.18632","volume":"7","author":[{"given":"Qing","family":"Li","sequence":"first","affiliation":[{"name":"Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaodong","family":"Zhong","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Zeng","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunrui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, the Central Hospital of Wuhan, Wuhan 430016, P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiming","family":"Li","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jue","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanjun","family":"Cheng","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anyuan","family":"Guo","sequence":"additional","affiliation":[{"name":"Bioinformatics and Molecular Imaging Key Laboratory, Department of Biomedical Engineering, Key Laboratory of Molecular Biophysics of the Ministry of Education, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Songya","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caibao","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojian","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"You","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Zou","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2016,8,13]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11899-012-0117-2","article-title":"Curing chronic myeloid leukemia","volume":"7","author":"Mahon","year":"2012","journal-title":"Curr Hematol Malig Rep"},{"key":"2","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Sawyers","year":"2001","journal-title":"N Engl J Med"},{"key":"3","doi-asserted-by":"crossref","first-page":"663","DOI":"10.6004\/jnccn.2013.0196","article-title":"Monitoring response to tyrosine kinase inhibitor therapy, mutational analysis, and new treatment options in chronic myelogenous leukemia","volume":"11","author":"Radich","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"key":"4","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/leu.2015.36","article-title":"Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV","volume":"29","author":"Falge","year":"2015","journal-title":"Leukemia"},{"key":"5","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Rousselot","year":"2010","journal-title":"Lancet Oncol"},{"key":"6","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3324\/haematol.2011.056853","article-title":"Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia","volume":"97","author":"Teshima","year":"2012","journal-title":"Haematologica"},{"key":"7","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"Mahon","year":"2007","journal-title":"Blood"},{"key":"8","first-page":"979","article-title":"Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation","volume":"90","author":"Lazzarino","year":"2005","journal-title":"Haematologica"},{"key":"9","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.4161\/15384101.2014.964107","article-title":"The metabolically-modulated stem cell niche: a dynamic scenario regulating cancer cell phenotype and resistance to therapy","volume":"13","author":"Sbarba","year":"2014","journal-title":"Cell Cycle"},{"key":"10","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1182\/blood-2014-08-588855","article-title":"shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance","volume":"125","author":"Heaton","year":"2015","journal-title":"Blood"},{"key":"11","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1182\/blood-2011-02-335497","article-title":"Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease","volume":"118","author":"Turhan","year":"2011","journal-title":"Blood"},{"key":"12","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.bcmd.2012.05.007","article-title":"Comprehensive profile of cytogenetics in 2308 Chinese children and adults with de novo acute myeloid leukemia","volume":"49","author":"Huang","year":"2012","journal-title":"Blood Cells Mol Dis"},{"key":"13","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s13277-011-0222-1","article-title":"Transcription suppression of SARI (suppressor of AP-1, regulated by IFN) by BCR-ABL in human leukemia cells","volume":"32","author":"Huang","year":"2011","journal-title":"Tumour Biol"},{"key":"14","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/eci.12368","article-title":"DPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemia","volume":"44","author":"Mayer","year":"2014","journal-title":"Eur J Clin Invest"},{"key":"15","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1182\/blood-2013-10-536078","article-title":"Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia","volume":"123","author":"Sperr","year":"2014","journal-title":"Blood"},{"key":"16","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1038\/leu.2014.51","article-title":"BCR-ABL1-positive microvesicles transform normal hematopoietic transplants through genomic instability: implications for donor cell leukemia","volume":"28","author":"Kong","year":"2014","journal-title":"Leukemia"},{"key":"17","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11899-015-0258-1","article-title":"Milestones and monitoring","volume":"10","author":"Saglio","year":"2015","journal-title":"Curr Hematol Malig Rep"},{"key":"18","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/asheducation.V2012.1.122.3798214","article-title":"Is going for cure in chronic myeloid leukemia possible and justifiable?","volume":"2012","author":"Mahon","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"19","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/13684730210002319","article-title":"Increased IFN-gamma synthesis by T cells from patients on imatinib therapy for chronic myeloid leukemia","volume":"7","author":"Messner","year":"2002","journal-title":"Cytokines Cell Mol Ther"},{"key":"20","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/nature03669","article-title":"Dynamics of chronic myeloid leukaemia","volume":"435","author":"Nowak","year":"2005","journal-title":"Nature"},{"key":"21","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1242\/jcs.064386","article-title":"Microvesicles: mediators of extracellular communication during cancer progression","volume":"123","author":"D'Souza-Schorey","year":"2010","journal-title":"J Cell Sci"},{"key":"22","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/978-1-4939-0856-1_11","article-title":"Microvesicles as mediators of intercellular communication in cancer","volume":"1165","author":"Cerione","year":"2014","journal-title":"Methods Mol Biol"},{"key":"23","first-page":"142","article-title":"The origin, function, and diagnostic potential of RNA within extracellular vesicles present in human biological fluids","volume":"4","author":"Gercel-Taylor","year":"2013","journal-title":"Front Genet"},{"key":"24","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/ncb1800","article-title":"Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers","volume":"10","author":"Breakefield","year":"2008","journal-title":"Nat Cell Biol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.11281","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T12:12:10Z","timestamp":1596715930000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.11281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,13]]},"references-count":24,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2016,9,6]]}},"alternative-id":["11281","27533462"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.11281","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,13]]}}}